Skip to main content
Caplight Logo









Onena Medicines

Onena Medicines

Private
AllschwilHealthcare & Life Scienceshttps://www.onenameds.com/

Last Round

Series A

Oct 31, 2023

Total Funding Raised

$6.57M

Company Overview

Onena Medicines is a biopharmaceutical company that utilizes an AI-centric platform for discovering and developing antibody-based medicines to treat recurrent and metastatic cancers and select rare diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

antibody therapydrug discoverybiotechAI drug discoveryin silico drug discoveryprecision medicineantibody designDSIP neutralizationbiopharmapreclinical biotechAI-driven medicinecomputational biologytherapeutic antibodydrug pipelinebiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Onena Medicines Comparables

Compare Onena Medicines with similar companies based on industry and business-model similarity.

Onena Medicines comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BigHat Biosciences
78%
LabGenius Therapeutics
76%
Ymmunobio
72%

Onena Medicines Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 31, 2023
GrantMar 1, 2023
AcceleratorFeb 1, 2022
SeedMar 1, 2020

Key People

Founding team and executive leadership

Neethan Lobo

CEO And Co-founder

Founding Team

Onena Medicines Investors

Notable investors and investment history

Onena Medicines investors
InvestorRounds
Avanteca PartnersSeries A
DeepTek Gipuzkoa FundazioaSeed
BaseLaunchAccelerator
Zurcher KantonalbankSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 31, 2023

    $4M round led by Zurcher Kantonalbank and Avanteca Partners

  • Feb 1, 2022

    $540K raised from BaseLaunch

Onena Medicines Filings

Explore SEC and related filing metadata, where available.

Onena Medicines filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Onena Medicines's valuation, stock price, and market status.

Is Onena Medicines a public or private company?

Onena Medicines is a private company.

What is the current stock price of Onena Medicines?

Onena Medicines is a private company with no public stock price. No recent secondary market data is available.

How much is Onena Medicines worth (valuation)?

Valuation information for Onena Medicines is not publicly available.

Can I buy Onena Medicines stock?

Onena Medicines shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Onena Medicines's last funding round?

Onena Medicines's most recent funding round was Series A on October 31, 2023.

Who are the main investors in Onena Medicines?

Key investors in Onena Medicines include Avanteca Partners, Zurcher Kantonalbank.

Will Onena Medicines IPO soon?

No public IPO plans have been announced for Onena Medicines.

How can I track Onena Medicines secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Onena Medicines's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersAllschwil
Employee Range6
Year Founded2019
Last FundingOct 31, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?